Based On Th17/Treg Balance To Explore The Mechanism Of Qingxuan Xingbi Therapy In The Treatment Of Allergic Rhinitis In Children(lung Meridian Fever Syndrome)

Objective Qingxuan Xingbi therapy is used to treat allergic rhinitis(AR)in children(lung meridian fever syndrome),Observing the different expression levele of ROR-γt,Foxp3,IL-17,IL-10,In order to explore the effect of the Qingxuan Xingbi therapy on the immune imbalance of Th17/Treg in children with AR(lung meridian fever syndrome),the drug mechanism of action of the method was clarified,and a scientific basis was provided for clinical application.MethodsIn this study,52 children who attended the pediatric outpatient clinic of the People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine and met the diagnostic criteria of children’s AR and the key points for the diagnosis of traditional Chinese medicine symptoms of lung meridian fever syndrome were randomly divided into 26 cases of Traditional Chinese medicine treatment group(group A)and 26 cases of Western medicine control group(group B),group A was treated with Qingxuan Xingbi therapy combined with Xingbi Gel Nasal Drops,and group B was treated with cetirizine tablets orally combined with mometasone furoate nasal spraying intervention,and the treatment was one course for four weeks.The relative expression levels of ROR-γt m RNA and Foxp3 m RNA in peripheral blood were determined by real time-PCR,the concentration levels of IL-17 and IL-10 were measured by ELISA,at the same time,the clinical symptoms,signs and quality of life,TCM syndrome points of children with AR before and after treatment were quantitatively scored to evaluate the clinical efficacy.SPSS23.0 statistical software statistics are used to perform statistical analysis of the collected data.Results1.The results of Real-time PCR test showed that after 4 weeks of treatment,the expression level of ROR-γt in children in groups A and B was significantly lower than before treatment(P<0.05),and the expression level of Foxp3 was significantly higher than before treatment(P<0.05).2.El ISA test results show that after 4 weeks of treatment,the concentration level of IL-10 in children in groups A and B was significantly higher than before treatment(P<0.05),and the concentration level of IL-17 was significantly lower than before treatment(P<0.05).3.Visual Analogue Scale(VAS): after 2 weeks and 4 weeks of treatment,the VAS scores of children in the A and B groups decreased significantly compared with before treatment(P<0.05);after 4 weeks of treatment,the nasal itch symptom scores were significantly different(P<0.05),and the effect of group A in relieving nasal itch symptoms was better than that in group B;there was no significant difference in the scores of sneezing,clear water,nasal congestion and overall symptoms(P>0.05).4.Paediatric Rhinoconjunctivitis Quality of Life Questionnaire(PRQLQ): After 2 weeks and4 weeks of treatment,the PRQLQ scores of both groups of children decreased significantly compared with before treatment(P<0.05).After 4 weeks of treatment,the improvement effect of ocular symptoms,non-nasal and ophthalmic symptoms and behavioral problems was significantly different(P<0.05),and group A was better than group B,and there was no significant difference in the scores of nasal symptoms and affective problems(P>0.05).5.TCM syndrome score: TCM syndrome score: After 2 weeks of treatment,the four concomitant disease scores of cough,itchy throat,dry mouth irritability and nosebleed in group A decreased significantly compared with before treatment(P<0.05),and there was no significant improvement in group B(P>0.05);after 4 weeks of treatment,the concomitant disease scores of group A and B decreased significantly compared with before treatment(P<0.05);and compared with the two groups,the improvement effect of group A in cough,itchy throat,dry mouth and thirst was better than that in group B(P<0.05).6.Efficacy evaluation results: After 2 weeks of treatment,the effective rates of groups A and B were 77% and 69%,respectively,and there was no significant difference between the two groups(P>0.05);after 4 weeks of treatment,the effective rates of groups A and B were 92%and 88%,respectively,and the efficacy of group A was significantly better than that of group B(P<0.05).ConclusionQingxuan Xingbi therapy can effectively treat AR(lung meridian fever syndrome),and its mechanism of action is to increase the level of IL-10 and Foxp3 in children with AR,reduce the level of IL-17 and ROR-γ t,and further correct the Th17/Treg immune imbalance.